| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Department of Pathology, Academic Hospital Vrije Universiteit, 1081 HV Amsterdam, the Netherlands [A. B. S., G. L. S., M. C. d. J., S. E. B., D. F. D., R. J. S.]; Department of Biological Chemistry, University of California at Los Angeles School of Medicine, Los Angeles, California 90095 [A. C. S., V. A. K., L. H. R.]; Department of Molecular Recognition, Institute for Animal Science and Health (ID-DLO), 8219 PH Lelystad, the Netherlands [J. W. S., R. H. M.]; and Institute for Hematology, Erasmus University Rotterdam, 3000 DR Rotterdam, the Netherlands [E. W.]
Vaults are 13 megadalton ribonucleoprotein particles composed largely of the major vault protein (MVP) and two high molecular weight proteins, p240 and p193, and a small vault RNA (vRNA). Increased levels of MVP expression, vault-associated vRNA, and vaults have been linked directly to multidrug resistance (MDR). To further define the putative role of vaults in MDR, we produced monoclonal antibodies against the Mr 193,000 vault protein and studied its expression levels in various multidrug-resistant cell lines. We find that, like MVP, p193 mRNA and protein levels are increased in various multidrug-resistant cell lines. Subcellular fractionation of vault particles revealed that vault-associated p193 levels are increased in multidrug-resistant cells as compared with the parental, drug-sensitive cells. Furthermore, protein analysis of postnuclear supernatants and coimmunoprecipitation studies show that drug-sensitive MVP-transfected tumor cells lack this up-regulation in vault-associated p193. Our observations indicate that vault formation is limited not only by the expression of the MVP but also by the expression or assembly of at least one of the other vault proteins.
This article has been cited by other articles:
![]() |
S. Raval-Fernandes, V. A. Kickhoefer, C. Kitchen, and L. H. Rome Increased Susceptibility of Vault Poly(ADP-Ribose) Polymerase-Deficient Mice to Carcinogen-Induced Tumorigenesis Cancer Res., October 1, 2005; 65(19): 8846 - 8852. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. van Zon, M. H. Mossink, M. Schoester, R. J. Scheper, P. Sonneveld, and E. A. C. Wiemer Efflux Kinetics and Intracellular Distribution of Daunorubicin Are Not Affected by Major Vault Protein/Lung Resistance-Related Protein (Vault) Expression Cancer Res., July 15, 2004; 64(14): 4887 - 4892. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. van Zon, M. H. Mossink, M. Schoester, A. B. Houtsmuller, G. L. Scheffer, R. J. Scheper, P. Sonneveld, and E. A. C. Wiemer The formation of vault-tubes: a dynamic interaction between vaults and vault PARP J. Cell Sci., November 1, 2003; 116(21): 4391 - 4400. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Mossink, A. van Zon, E. Franzel-Luiten, M. Schoester, V. A. Kickhoefer, G. L. Scheffer, R. J. Scheper, P. Sonneveld, and E. A. C. Wiemer Disruption of the Murine Major Vault Protein (MVP/LRP) Gene Does Not Induce Hypersensitivity to Cytostatics Cancer Res., December 15, 2002; 62(24): 7298 - 7304. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Schroeijers, A. W. Reurs, G. L. Scheffer, A. G. M. Stam, M. C. de Jong, T. Rustemeyer, E. A. C. Wiemer, T. D. de Gruijl, and R. J. Scheper Up-Regulation of Drug Resistance-Related Vaults During Dendritic Cell Development J. Immunol., February 15, 2002; 168(4): 1572 - 1578. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Zembutsu, Y. Ohnishi, T. Tsunoda, Y. Furukawa, T. Katagiri, Y. Ueyama, N. Tamaoki, T. Nomura, O. Kitahara, R. Yanagawa, et al. Genome-wide cDNA Microarray Screening to Correlate Gene Expression Profiles with Sensitivity of 85 Human Cancer Xenografts to Anticancer Drugs Cancer Res., January 1, 2002; 62(2): 518 - 527. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Schroeijers, G. L. Scheffer, A. W. Reurs, A. C.L.M. Pijnenborg, C. Abbondanza, E. A.C. Wiemer, and R. J. Scheper Detection of the Mr 110,000 Lung Resistance-related Protein LRP/MVP with Monoclonal Antibodies J. Histochem. Cytochem., November 1, 2001; 49(11): 1379 - 1386. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Perkins, D. Sun, A. Nguyen, S. Tulac, M. Francesco, H. Tavana, H. Nguyen, S. Tugendreich, P. Barthmaier, J. Couto, et al. Novel Inhibitors of Poly(ADP-ribose) Polymerase/PARP1 and PARP2 Identified Using a Cell-based Screen in Yeast Cancer Res., May 1, 2001; 61(10): 4175 - 4183. [Abstract] [Full Text] |
||||
![]() |
A. van Zon, M. H. Mossink, M. Schoester, G. L. Scheffer, R. J. Scheper, P. Sonneveld, and E. A. C. Wiemer Multiple Human Vault RNAs. EXPRESSION AND ASSOCIATION WITH THE VAULT COMPLEX J. Biol. Chem., September 28, 2001; 276(40): 37715 - 37721. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |